Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-07-11

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

This report forcasts 10 year sales forecast for all major drugs brands in the asthma and COPD markets, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets.


Scope

  • Indication based forecasts for asthma/COPD products and significant pipeline drugs
  • Assessment of country-specific drivers and resistors likely to impact the market
  • Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates
  • Market overview by geographical area, with value analysis of clinical and commercial factors underlying product performance


    • Report Highlights
    Asthma/COPD sales in the seven major markets are expected to grow to over $24 billion annually by 2010 and drop slightly thereafter due to patent expiries of key products. The ICS/LABA class is set to remain the leading class by value throughout, while the LAMA market will experience the strongest growth, particularly in COPD.

    A once-daily LABA/LAMA product should become the top-selling single brand in the seven major markets in 2016, depending on which company launches such a combination product first. However, combined sales of the Advair franchise (Advair/Seretide and once-daily Beyond Advair) will dominate the asthma/COPD market over the next ten years.

    The phase-out of CFC-containing inhalers in the US after 2008 will have a big impact on the market for short-acting beta2-agonists (SABAs), increasing this class' size significantly. The main beneficiary is expected to be IVAX's (now Teva) ProAir due to its favourable price compared with other marketed HFA SABAs.


    Reasons to Purchase

  • Identify key opportunities and threats that will impact the use and uptake of new and existing products
  • Quantify the future size and scope of the asthma/COPD market and predict the future performance of key compounds
  • Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development

    • Table of Contents

    Other users found this report page using the following search terms: copd asthma emphysema bronchitis respiratory respimat berodual uk combivent brovana inhaled buy new vs novolizer

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.